Nuravax and others are working on the next wave of Alzheimer’s treatments to catch the disease before symptoms arise.

Lilly dominates GLP-1 market but faces near-term headwinds, while AstraZeneca boasts steady growth, rising estimates and a higher dividend yield.

Helix has released a new suite of pharmacogenomics (PGx) tests, widening its portfolio in neurology and oncology.

Let's consider two corporations that could help you do better than average in the next decade: Eli Lilly (NYSE: LLY) and ...

Lending support to his choice, Rocket Companies, on May 8, posted better-than-expected quarterly sales. Markets expect rate ...

The Lumipulse blood test became the first “in vitro diagnostic device” to be endorsed by the U.S. Food and Drug ...

Eli Lilly says a new starting dose regimen for its Alzheimer's disease therapy Kisunla reduces the risk of side effects that have stood in the way of approvals and reimbursement decisions for ...

The stock market volatility will only worsen as the U.S. continues to threaten its trade partners with tariffs. Investors do ...

Eli Lilly's growth is impressive, but its current valuation is only justifiable with sustained high growth. Click here to ...

The EMA's human medicines committee has said it does not recommend approval of Eli Lilly's anti-amyloid Alzheimer's disease treatment Kisunla, saying its modest benefits don't outweigh its risks.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Helix, a leader in precision health, is announcing the release of a new suite of pharmacogenomics (PGx) tests, including a test designed to identify patients with DYPD gene variants who may be at ...